Vanadium and insulin increase adiponectin production in 3T3-L1 adipocytes

Pharmacological Research

Volumn 54, Issue 1, 2006, Pages 30-38

  Seale, Andre P ^a   de Jesus, Lucia A ^a   Park, Min Chul ^a   Kim, Yang Sun ^a  

^a Proteonik Inc   (South Korea)

Author keywords

Adipocyte; Adiponectin; Insulin; Signal transduction; Vanadium

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADIPONECTIN; AGL 2263; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; UNCLASSIFIED DRUG; VANADIUM; VANADYL SULFATE; WORTMANNIN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; INSULIN SENSITIVITY; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; INSULIN; MICE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; VANADIUM;

EID: 33745073605     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.01.013     Document Type: Article

References (42)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Lyonnet B., Martz X., and Martin E. L'emploi therapeutique des derives du vanadium. Presse Med 1 (1899) 191
3. Srivastava A.K., and Mehdi M.Z. Insulino-mimetic and anti-diabetic effects of vanadium compounds. Diabet Med 22 (2005) 2-13
4. Shechter Y., Goldwaser I., Mironchik M., Fridkin M., and Gefel D. Historic perspective and recent developments on the insulin-actions of vanadium; toward developing vanadium-based drugs for diabetes. Coord Chem Rev 237 (2003) 3-11
5. Mukherjee B., Patra B., Mahapatra S., Banerjee P., Tiwari A., and Chatterjee M. Vanadium-an element of atypical biological significance. Toxicol Lett 150 (2004) 135-143
6. Yuen V.G., Orvig C., and McNeill J.H. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can J Physiol Pharmacol 73 (1995) 55-64
7. Sakurai H., Tsuchiya K., Nukatsuka M., Sofue M., and Kawada J. Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats. J Endocrinol 126 (1990) 451-459
8. Meyerovitch J., Farfel Z., Sack J., and Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J Biol Chem 262 (1987) 6658-6662
9. Green A. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. Biochem J 238 (1986) 663-669
10. Mohammad A., Sharma V., and McNeill J.H. Vanadium increases GLUT4 in diabetic rat skeletal muscle. Mol Cell Biochem 233 (2002) 139-143
11. O'Connor J.C., and Freund G.G. Vanadate and rapamycin synergistically enhance insulin-stimulated glucose uptake. Metabolism 52 (2003) 666-674
12. Rehder D., Costa Pessoa J., Geraldes C.F., Castro M.C., Kabanos T., Kiss T., et al. In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds. J Biol Inorg Chem 7 (2002) 384-396
13. 4) as the active component. J Inorg Biochem 96 (2003) 321-330
14. Mohammad A., Wang J., and McNeill J.H. Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo. Mol Cell Biochem 229 (2002) 125-128
15. Havel P.J. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53 Suppl. 1 (2004) S143-S151
16. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
17. Halleux C.M., Takahashi M., Delporte M.L., Detry R., Funahashi T., Matsuzawa Y., et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288 (2001) 1102-1107
18. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
19. Kappes A., and Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 32 (2000) 548-554
20. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301 (2003) 1045-1050
21. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
22. Bogan J.S., and Lodish H.F. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP-30 and GLUT4. J Cell Biol 146 (1999) 609-620
23. Clarke K.J., Zhong Q., Schwartz D.D., Coleman E.S., Kemppainen R.J., and Judd R.L. Regulation of adiponectin secretion by endothelin-1. Biochem Biophys Res Commun 312 (2003) 945-949
24. Fasshauer M., Klein J., Neumann S., Eszlinger M., and Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290 (2002) 1084-1089
25. Blum G., Gazit A., and Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278 (2003) 40442-40454
26. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 26 (2005) 439-451
27. Winter C.L., Lange J.S., Davis M.G., Gerwe G.S., Downs T.R., Peters K.G., et al. A Nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in zucker diabetic fatty rats. Exp Biol Med (Maywood) 230 (2005) 207-216
28. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein ACRP-30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
29. Seale A.P., de Jesus L.A., Kim S.Y., Choi Y.H., Lim H.B., Hwang C.S., et al. Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and zinc(II) complexes. Biotechnol Lett 27 (2005) 221-225
30. Tardif A., Julien N., Chiasson J.L., and Coderre L. Stimulation of glucose uptake by chronic vanadate pretreatment in cardiomyocytes requires PI 3-kinase and p38 MAPK activation. Am J Physiol Endocrinol Metab 284 (2003) E1055-E1064
31. Pandey S.K., Anand-Srivastava M.B., and Srivastava A.K. Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation. Biochemistry 37 (1998) 7006-7014
32. Sekar N., Li J., He Z., Gefel D., and Shechter Y. Independent signal-transduction pathways for vanadate and for insulin in the activation of glycogen synthase and glycogenesis in rat adipocytes. Endocrinology 140 (1999) 1125-1131
33. Tsiani E., Bogdanovic E., Sorisky A., Nagy L., and Fantus I.G. Tyrosine phosphatase inhibitors, vanadate and pervanadate, stimulate glucose transport and GLUT translocation in muscle cells by a mechanism independent of phosphatidylinositol 3-kinase and protein kinase C. Diabetes 47 (1998) 1676-1686
34. Li J., Elberg G., Sekar N., bin He Z., and Shechter Y. Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanisms. Endocrinology 138 (1997) 2274-2279
35. Mohammad A., Bhanot S., and McNeill J.H. In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle. Mol Cell Biochem 223 (2001) 103-108
36. Hajduch E., Litherland G.J., and Hundal H.S. Protein kinase B (PKB/Akt)-a key regulator of glucose transport?. FEBS Lett 492 (2001) 199-203
37. Burgering B.M., and Kops G.J. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 27 (2002) 352-360
38. Davis K.E., Moldes M., and Farmer S.R. The forkhead transcription factor FoxC2 inhibits white adipocyte differentiation. J Biol Chem 279 (2004) 42453-42461
39. Hinault C., Mothe-Satney I., Gautier N., Lawrence Jr. J.C., and Van Obberghen E. Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice. FASEB J 18 (2004) 1894-1896
40. Stratford S., Hoehn K.L., Liu F., and Summers S.A. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 279 (2004) 36608-36615
41. Gorin Y., Kim N.H., Feliers D., Bhandari B., Choudhury G.G., and Abboud H.E. Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase. FASEB J 15 (2001) 1909-1920
42. Kadowaki T., Hara K., Yamauchi T., Terauchi Y., Tobe K., and Nagai R. Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 228 (2003) 1111-1117